Published online August 26, 2008
Diabetes
57:3069-3077,
2008
DOI: 10.2337/db08-0878
© 2008 by the American Diabetes Association
β-Cell Proliferation, but Not Neogenesis, Following 60% Partial Pancreatectomy Is Impaired in the Absence of FoxM1
Amanda Ackermann Misfeldt1,2,
Robert H. Costa3, and
Maureen Gannon1,2,4,5
1 Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee
2 Program in Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee
3 Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois
4 Department of Medicine, Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, Tennessee
5 Department of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee
Corresponding author: Maureen Gannon, maureen.gannon{at}vanderbilt.edu
OBJECTIVE—This study was designed to determine whether the transcription factor FoxM1 was required for regeneration of β-cell mass via proliferation and/or neogenesis in the adult after 60% partial pancreatectomy (PPx).
RESEARCH DESIGN AND METHODS—Adult mice with a pancreas-wide deletion of Foxm1 (Foxm1flox/flox;Pdx1-Cre [FoxM1 panc]) and their control littermates (Foxm1flox/flox) were subjected to PPx or a sham operation, after which islet expression of Foxm1 and several target genes, β-cell mass, proliferation, β-cell size, islet size, islet density, and neurogenin-3 expression were analyzed.
RESULTS—In control mice, PPx stimulated β-cell proliferation and neogenesis and upregulated Foxm1 and several of its known targets (Plk1, Cenp-a, Birc5/Survivin, and Ccnb1) in islets. Within 1 week post-PPx, control mice underwent significant regeneration of β-cell mass, and average islet size within the regenerating lobe was similar to that after a sham operation. However, FoxM1 panc mice exhibited specific impairments in β-cell mass regeneration and islet growth after PPx, with reduced proliferation of - and β-cells but no impairments in acinar or ductal cell proliferation. Interestingly, FoxM1 was not required for proliferation of β-cells within small endocrine cell clusters located in the regenerating portion of the pancreas but was specifically required for proliferation of β-cells within larger islets. Additionally, FoxM1 was not required for β-cell neogenesis following PPx.
CONCLUSIONS—Our results indicate that FoxM1 is partially required for increased β-cell proliferation, but not β-cell neogenesis, stimulated by PPx. Furthermore, FoxM1 seems to be dispensable for proliferation of β-cells following neogenesis but is required for proliferation of preexisting β-cells.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
Copyright © 2008 by the American Diabetes Association.
|
|
| |
|